ANKYLOSING SPONDYLITIS - ADALIMUMAB, ETANERCEPT AND INFLIXIMAB

NICE Appraisal 

TA143  Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis


DSU Reports

Ankylosing spondylitis: a comparison of cost effectiveness models (May 2007)

Comparisons of submitted models for the appraisal of etanercept, adalimumab and infliximab for ankylosing spondylitis (February 2007)


Related publications

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply Rheumatology 2008; Vol 47 (10): 1590

A Wailoo, N Bansback, J Chilcott.Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance Rheumatology 2008;
Vol 47 (2): 119-120


 To receive notification when new reports or documents are uploaded to this website, please join our mailing list by entering your details on the right of this page or follow us on Twitter @NICE_DSU